How Much Does Jatenzo Cost in Wisconsin in 2026?

Wisconsin Retail and Cash-Pay Pricing

The average cash-pay price for Jatenzo at Wisconsin retail pharmacies sits at approximately $900 per month in 2026, matching Tolmar's manufacturer list price. This figure applies to a 30-day supply of the standard twice-daily dosing regimen.

Prices vary by pharmacy location and type. Independent pharmacies in Milwaukee, Madison, and Green Bay may quote slightly different dispensing fees, but the wholesale acquisition cost remains consistent statewide. Large chain pharmacies (CVS, Walgreens, Walmart) typically price within $20 of one another for brand-name Jatenzo. No generic oral testosterone undecanoate is currently available in the United States, which keeps competitive pricing pressure low 1.

For context on the clinical profile behind this pricing, the key registration trial by Swerdloff et al. (2020) enrolled 166 hypogonadal men and demonstrated that 87% of subjects on the 237 mg twice-daily dose achieved steady-state serum testosterone within the eugonadal range (300 to 1 to 100 ng/dL) 2. That efficacy benchmark is what supports Jatenzo's positioning as a premium oral alternative to injectable testosterone cypionate, which costs $30 to $80 per month in generic form 3.

Wisconsin patients paying cash should request a price match or ask the pharmacist to run the Tolmar savings card before filling. Even without insurance, manufacturer discount programs sometimes reduce out-of-pocket cost.

Wisconsin Medicaid Coverage

Wisconsin Medicaid does cover Jatenzo, but a prior authorization (PA) is required before the state program will pay for the prescription. The PA process typically requires documentation of a confirmed diagnosis of male hypogonadism with two morning serum testosterone levels below 300 ng/dL, consistent with Endocrine Society guidelines 4.

The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with symptomatic testosterone deficiency confirmed by repeated low morning total testosterone measurements 4. Wisconsin Medicaid formulary rules generally require that prescribers document why oral testosterone undecanoate is preferred over lower-cost alternatives like intramuscular testosterone cypionate or topical gels.

PA approval timelines in Wisconsin typically run 3 to 7 business days. Denials can be appealed through the Wisconsin Department of Health Services Fair Hearing process. Prescribers should include the following in PA submissions: lab confirmation of hypogonadism (two separate morning draws), documentation of symptoms (fatigue, decreased libido, reduced muscle mass), and a clinical rationale for selecting the oral route over injectables 5.

One practical consideration: patients switching from injectable testosterone to Jatenzo under Wisconsin Medicaid should confirm that their provider submits the PA before the last injection's therapeutic window closes, preventing gaps in treatment coverage.

Commercial Insurance Coverage in Wisconsin

Major commercial insurers operating in Wisconsin (including Anthem Blue Cross Blue Shield, Quartz, Group Health Cooperative of South Central Wisconsin, and UnitedHealthcare) vary in their Jatenzo formulary placement. Most place Jatenzo on specialty or non-preferred brand tiers, resulting in copays of $50 to $150 per month before any manufacturer assistance.

Step therapy is common. Several Wisconsin plans require documented failure of, intolerance to, or contraindication for at least one first-line testosterone formulation (typically injectable testosterone cypionate or a topical gel like AndroGel) before approving Jatenzo 6. The FDA's own labeling for Jatenzo notes it is indicated for testosterone replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone 1.

Patients can check their specific plan's formulary through their insurer's online portal or by calling the member services number on their insurance card. For employer-sponsored plans, the benefits coordinator may have details on specialty pharmacy requirements.

A 2022 analysis in the Journal of the Endocrine Society found that out-of-pocket costs for branded testosterone formulations were a primary driver of therapy discontinuation, with 28.4% of patients citing cost as the reason they stopped treatment 7. Keeping copays manageable through savings cards or formulary exceptions directly affects adherence.

The Tolmar Savings Card

Tolmar, Jatenzo's manufacturer, offers a copay savings card that can reduce out-of-pocket costs to $0 per month for eligible commercially insured patients. The program covers up to a specified annual maximum in copay assistance.

Eligibility requirements: the patient must have commercial (private) insurance, must not be enrolled in any federal or state-funded healthcare program (Medicare, Medicaid, Tricare, VA), and must have a valid Jatenzo prescription. Wisconsin residents with commercial insurance can enroll online through Tolmar's patient support website or by calling the number on the savings card.

The savings card works at point of sale. The pharmacist processes insurance first, then applies the savings card to reduce the remaining copay. Patients should present both their insurance card and the Tolmar savings card at the pharmacy counter.

Limitations apply. The card typically cannot be combined with other manufacturer coupons. Annual caps on total assistance mean patients on higher-cost plans may exhaust benefits before the 12-month mark. Renewal is required annually.

For uninsured patients, Tolmar also maintains a patient assistance program (PAP) with income-based eligibility. Patients at or below 400% of the federal poverty level may qualify for free medication directly from the manufacturer 8.

Compounded Oral Testosterone Undecanoate in Wisconsin

Compounded oral testosterone undecanoate is available in Wisconsin through licensed 503A compounding pharmacies. These pharmacies prepare patient-specific prescriptions under state pharmacy board oversight.

The cost for compounded oral testosterone undecanoate is substantially lower than brand Jatenzo, though prices vary by pharmacy, dose strength, and quantity dispensed. Some Wisconsin 503A compounders quote prices ranging from $75 to $200 per month, far below the $900 brand price.

Wisconsin law permits 503A compounding pharmacies to prepare testosterone undecanoate capsules when a licensed prescriber writes a patient-specific prescription. The pharmacy must hold valid Wisconsin Department of Safety and Professional Services licensure. Federal law under the Drug Quality and Security Act (2013) distinguishes between 503A (patient-specific) and 503B (outsourcing facility) compounding 9.

Key differences from brand Jatenzo: compounded formulations have not undergone FDA-reviewed bioequivalence testing. The Swerdloff et al. trial data on pharmacokinetics, including the self-emulsifying drug delivery system (SEDDS) that gives Jatenzo its specific absorption profile, apply only to the branded product 2. Absorption of oral testosterone undecanoate is highly fat-dependent. The FDA label specifies that Jatenzo must be taken with food, and the SEDDS technology was designed to improve lymphatic absorption and reduce first-pass hepatic metabolism 10.

Patients considering compounded oral testosterone undecanoate should discuss absorption variability with their prescriber and plan for follow-up serum testosterone monitoring within the first month.

Telehealth Access for Wisconsin Patients

Wisconsin permits telehealth prescribing of Jatenzo. Patients can receive a diagnosis of hypogonadism and obtain a Jatenzo prescription through a licensed telemedicine provider without an in-person visit, provided the prescriber holds an active Wisconsin medical license.

Wisconsin's telehealth parity law (Wis. Stat. § 49.45(61)) requires Medicaid to cover telehealth services at the same rate as in-person visits. Commercial insurers in Wisconsin are also required to cover telehealth under the state's telehealth coverage mandate 11.

The telehealth workflow for Jatenzo typically involves: an initial video consultation, review of symptoms (low energy, decreased libido, mood changes, reduced muscle mass), ordering of laboratory tests (total testosterone, free testosterone, LH, FSH, CBC, metabolic panel), and a follow-up visit to discuss results and initiate therapy. Blood draws must be completed at a local Wisconsin lab (Quest, Labcorp, or hospital-affiliated facilities) 12.

Testosterone levels should be drawn in the morning, ideally between 7:00 and 10:00 AM, on two separate occasions before initiating therapy. The Endocrine Society recommends confirming hypogonadism with repeated measurements because testosterone exhibits circadian variation, with peak levels in the early morning 4.

Jatenzo vs. Other Testosterone Formulations: Wisconsin Cost Comparison

Understanding how Jatenzo's price compares to alternatives helps Wisconsin patients make informed decisions with their prescribers.

Injectable testosterone cypionate (generic) runs $30 to $80 per month for most Wisconsin patients and remains the lowest-cost option. It requires intramuscular injection every 1 to 2 weeks 13. Topical testosterone gels (generic versions of AndroGel 1%) cost approximately $50 to $150 per month and require daily application with transfer precautions 14. Testosterone nasal gel (Natesto) costs approximately $500 to $700 per month and requires three-times-daily intranasal dosing 15. Testosterone pellets (Testopel) cost $500 to $1,200 per insertion every 3 to 6 months, requiring an in-office procedure 16.

Jatenzo's oral convenience carries a price premium. For patients who strongly prefer avoiding injections, topical application, or nasal dosing, the oral route may justify the higher cost, particularly with savings card support.

A 2020 cardiovascular safety analysis of oral testosterone undecanoate found no significant increase in major adverse cardiovascular events (MACE) compared to placebo over 12 months of treatment, though the FDA label carries a class-wide cardiovascular warning for all testosterone products 17. The TRAVERSE trial (N=5,246) later confirmed that testosterone replacement therapy did not increase the incidence of MACE in men aged 45 to 80 with hypogonadism and established cardiovascular disease or high cardiovascular risk 18.

Monitoring and Follow-Up Costs

Beyond the medication itself, Wisconsin patients should budget for monitoring labs and follow-up visits. The Endocrine Society recommends checking serum testosterone, hematocrit, and PSA at 3 to 6 months after starting therapy, then annually 4.

Hematocrit monitoring is particularly important with any testosterone formulation. Polycythemia (hematocrit above 54%) is the most common adverse effect of testosterone therapy and may require dose reduction, phlebotomy, or treatment discontinuation 19. In the Swerdloff et al. Jatenzo trial, the incidence of hematocrit elevation above 54% was 3.6%, lower than rates typically reported with injectable formulations 2.

Lab costs in Wisconsin vary: a basic testosterone level runs $25 to $75 at cash-pay rates through Quest or Labcorp, while a comprehensive panel (total testosterone, free testosterone, estradiol, CBC, CMP, lipids, PSA) may cost $150 to $300 without insurance. Most Wisconsin commercial plans cover routine monitoring labs with standard copays.

For Jatenzo specifically, the FDA label recommends checking serum testosterone approximately 21 days after starting therapy or adjusting the dose, then periodically thereafter 1. The unique pharmacokinetics of the SEDDS formulation mean that steady-state levels are reached faster than with injectable depots, allowing for earlier dose titration.

Tips to Reduce Your Jatenzo Cost in Wisconsin

Start with the Tolmar savings card if you carry commercial insurance. Apply for Tolmar's patient assistance program if you are uninsured and meet income criteria. Ask your prescriber to submit a prior authorization to Wisconsin Medicaid if you are enrolled. Compare prices at multiple Wisconsin pharmacies using GoodRx or RxSaver price-comparison tools. Discuss compounded oral testosterone undecanoate with your prescriber as a lower-cost alternative, understanding the absorption differences. Use telehealth to reduce visit costs if your insurer covers virtual appointments at parity.

Dr. Shalender Bhasin, principal investigator of the TRAVERSE trial, has stated: "Testosterone replacement in men with hypogonadism and cardiovascular risk factors did not result in a higher incidence of major adverse cardiac events than placebo" 18. This finding supports the safety profile for patients choosing testosterone therapy, including oral formulations like Jatenzo.

The Endocrine Society guideline explicitly recommends "against testosterone therapy in men planning fertility in the near term" because exogenous testosterone suppresses spermatogenesis through negative feedback on the hypothalamic-pituitary-gonadal axis 4. Wisconsin patients of reproductive age should discuss fertility preservation before starting Jatenzo.